Skye Bioscience, Inc. (SKYE)
USD 3.01
(-7.38%)
USD 3.01
(-7.38%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -13.54 Million USD | -12.03% |
| 2022 | -12.09 Million USD | -54.73% |
| 2021 | -7.81 Million USD | -24.31% |
| 2020 | -6.28 Million USD | 5.37% |
| 2019 | 2.04 Million USD | -37.61% |
| 2018 | -4.69 Million USD | -28.81% |
| 2017 | -3.85 Million USD | 35.35% |
| 2016 | - USD | -21.08% |
| 2015 | - USD | -75.43% |
| 2014 | - USD | -2167.18% |
| 2013 | -7242.00 USD | -2632.13% |
| 2012 | 4755.00 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -5.69 Million USD | -40.42% |
| 2024 Q2 | -7.41 Million USD | -30.13% |
| 2023 Q2 | -2.95 Million USD | 33.29% |
| 2023 Q1 | -4.42 Million USD | -40.67% |
| 2023 Q4 | -4.05 Million USD | -18.49% |
| 2023 FY | - USD | -12.03% |
| 2023 Q3 | -3.42 Million USD | -16.0% |
| 2022 Q4 | -3.14 Million USD | -8.71% |
| 2022 Q1 | -2.86 Million USD | -17.4% |
| 2022 Q2 | -3.19 Million USD | -11.52% |
| 2022 Q3 | -2.89 Million USD | 9.31% |
| 2022 FY | - USD | -54.73% |
| 2021 Q3 | -1.81 Million USD | 0.93% |
| 2021 Q4 | -2.43 Million USD | -34.51% |
| 2021 Q2 | -1.82 Million USD | -5.32% |
| 2021 Q1 | -1.73 Million USD | -31.87% |
| 2021 FY | - USD | -24.31% |
| 2020 FY | - USD | 5.37% |
| 2020 Q3 | -1.53 Million USD | -26.02% |
| 2020 Q2 | -1.22 Million USD | 44.8% |
| 2020 Q4 | -1.31 Million USD | 14.38% |
| 2020 Q1 | -2.21 Million USD | -19.14% |
| 2019 Q3 | -1.5 Million USD | 15.12% |
| 2019 FY | - USD | -37.61% |
| 2019 Q2 | -1.77 Million USD | -16.89% |
| 2019 Q4 | -1.85 Million USD | -23.51% |
| 2019 Q1 | -1.51 Million USD | -34.05% |
| 2018 FY | - USD | -28.81% |
| 2018 Q4 | -1.12 Million USD | -8.11% |
| 2018 Q3 | -1.04 Million USD | 3.18% |
| 2018 Q2 | -1.07 Million USD | 31.37% |
| 2018 Q1 | -1.57 Million USD | -179.96% |
| 2017 FY | - USD | 35.35% |
| 2017 Q4 | -561.93 Thousand USD | 46.03% |
| 2017 Q1 | -1.39 Million USD | -108.65% |
| 2017 Q2 | -754.93 Thousand USD | 45.7% |
| 2017 Q3 | -1.04 Million USD | -37.92% |
| 2016 Q2 | -3.5 Million USD | -334.98% |
| 2016 FY | - USD | -21.08% |
| 2016 Q3 | -824.58 Thousand USD | 76.46% |
| 2016 Q4 | -666.32 Thousand USD | 19.19% |
| 2016 Q1 | -805.15 Thousand USD | 30.09% |
| 2015 FY | - USD | -75.43% |
| 2015 Q3 | -893.62 Thousand USD | 34.01% |
| 2015 Q4 | -1.15 Million USD | -28.89% |
| 2015 Q2 | -1.35 Million USD | -49.22% |
| 2015 Q1 | -907.51 Thousand USD | 46.6% |
| 2014 Q4 | -1.69 Million USD | -98.16% |
| 2014 Q3 | -857.61 Thousand USD | -11170.26% |
| 2014 Q2 | 7747.00 USD | 171.51% |
| 2014 Q1 | -10.83 Thousand USD | -798.52% |
| 2014 FY | - USD | -2167.18% |
| 2013 Q1 | 7628.00 USD | 245.02% |
| 2013 Q2 | 4692.00 USD | -38.49% |
| 2013 Q3 | -2510.00 USD | -153.5% |
| 2013 Q4 | 1551.00 USD | 161.79% |
| 2013 FY | - USD | -2632.13% |
| 2012 FY | - USD | 0.0% |
| 2012 Q1 | -381.00 USD | 0.0% |
| 2012 Q2 | 55.00 USD | 114.44% |
| 2012 Q3 | 4902.00 USD | 8812.73% |
| 2012 Q4 | -5260.00 USD | -207.3% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 80.929% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -128.5% |
| SQZ Biotechnologies Company | -64.14 Million USD | 78.878% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 22.006% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 114.406% |
| Mesoblast Limited | -62.38 Million USD | 78.286% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -781.974% |
| Genus plc | 73.7 Million USD | 118.382% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -104.908% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -281.944% |
| Marizyme, Inc. | -34.28 Million USD | 60.481% |
| ContraFect Corporation | -64.99 Million USD | 79.157% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -54.441% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -199.314% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -866.434% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -412.302% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -482.986% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -2515.125% |
| Accustem Sciences Inc. | -3.74 Million USD | -261.613% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 71.909% |
| EV Biologics, Inc. | -1.26 Million USD | -969.151% |
| Q BioMed Inc. | -617.62 Thousand USD | -2093.481% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 479.271% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -2042.224% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -493.023% |
| Biomind Labs Inc. | -1.03 Million USD | -1209.513% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 237.163% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -89.178% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -810.814% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -54090.2% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -248.775% |
| IMV Inc. | -35.52 Million USD | 61.863% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 14.633% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -441.477% |
| GB Sciences, Inc. | -1.41 Million USD | -854.13% |
| Alpha Cognition Inc. | -9.7 Million USD | -39.585% |
| HST Global, Inc. | -5303.00 USD | -255369.546% |
| CSL Limited | 4.78 Billion USD | 100.283% |
| Halberd Corporation | -74.27 Thousand USD | -18138.735% |
| Enzolytics Inc. | -2.12 Million USD | -538.424% |
| Resverlogix Corp. | -11.74 Million USD | -15.377% |
| Affymax, Inc. | -14.29 Million USD | 5.229% |
| SYBLEU INC | -141.57 Thousand USD | -9469.439% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -342.294% |
| argenx SE | -216.02 Million USD | 93.729% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 75.519% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 1213.192% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -803.829% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 3676.023% |
| AVAX Technologies, Inc. | -6.11 Million USD | -121.632% |
| Zenith Capital Corp. | -8.6 Million USD | -57.42% |
| Genscript Biotech Corporation | -248.71 Million USD | 94.553% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -77665.628% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -453.761% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -7596.406% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 65.821% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -368.396% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -1194.791% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 201580.518% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -674.146% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -605.267% |
| BioStem Technologies, Inc. | -7.55 Million USD | -79.351% |
| ONE Bio Corp. | 13.61 Million USD | 199.519% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -7381.197% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -558.607% |
| Agentix Corp. | -1.37 Million USD | -887.606% |
| LadRx Corporation | 412.28 Thousand USD | 3385.983% |
| Cell Source, Inc. | -4.27 Million USD | -217.085% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -3589.209% |
| Regen BioPharma, Inc. | 1.46 Million USD | 1024.144% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -1345.922% |
| NovAccess Global Inc. | -1.03 Million USD | -1209.199% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 253.014% |
| Itoco Inc. | -1.86 Million USD | -624.857% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -3468.713% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1113.938% |
| Kadimastem Ltd | -2.62 Million USD | -416.219% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -5564.876% |
| CytoDyn Inc. | -18.02 Million USD | 24.857% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -17042.505% |
| Mobile Lads Corp. | -2.24 Million USD | -504.489% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -110682.157% |
| Qrons Inc. | -40.08 Thousand USD | -33700.429% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -2689.41% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 2668.582% |
| Rebus Holdings, Inc. | -951 Thousand USD | -1324.558% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -1175.652% |
| International Stem Cell Corporation | 202 Thousand USD | 6806.708% |
| Bioxytran, Inc. | -3.82 Million USD | -254.634% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -25636.227% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -450.281% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 62.23% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -30005.667% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -394.797% |
| Neutra Corp. | -181.24 Thousand USD | -7374.634% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 32.797% |
| PureTech Health plc | -11.62 Million USD | -16.518% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 32.792% |
| IXICO plc | -707 Thousand USD | -1816.202% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -76.286% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 71.978% |
| CSL Limited | 4.73 Billion USD | 100.286% |
| Cellectis S.A. | -92.63 Million USD | 85.376% |